Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

Autor: Femke M. Prins, Iwan J. Hidding, Marjolein A.Y. Klaassen, Valerie Collij, Johannes P.D. Schultheiss, Werna T.C. Uniken Venema, Amber Bangma, Jurne B. Aardema, Bernadien H. Jansen, Wout G.N. Mares, Ben J.M. Witteman, Eleonora A.M. Festen, Gerard Dijkstra, Marijn C. Visschedijk, Herma H. Fidder, Arnau Vich Vila, Bas Oldenburg, Ranko Gacesa, Rinse K. Weersma

Publikováno v: Gut Microbes, Vol 16, Iss 1 (2024)

Emerging evidence suggests the gut microbiome’s potential in predicting response to biologic treatments in patients with inflammatory bowel disease (IBD). In this prospective study, we aimed to predict treatment response to vedolizumab and ustekinu

Externí odkaz: https://doaj.org/article/75c0bb382cf0416fa8df443a241eb914

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis

Autor: Mick J.M. van Eijs, José J.M. ter Linde, Matthijs J.D. Baars, Mojtaba Amini, Miangela M. Laclé, Eelco C. Brand, Eveline M. Delemarre, Julia Drylewicz, Stefan Nierkens, Rik J. Verheijden, Bas Oldenburg, Yvonne Vercoulen, Karijn P.M. Suijkerbuijk, Femke van Wijk

Publikováno v: iScience, Vol 26, Iss 10, Pp 107891- (2023)

Summary: Colitis is a prevalent adverse event associated with immune checkpoint inhibitor (ICI) therapy with similarities to inflammatory bowel disease. Incomplete mechanistic understanding of ICI colitis curtails evidence-based treatment. Given the

Externí odkaz: https://doaj.org/article/275e4beac3b94af3a05ead771f3af228

Homeostatic Function and Inflammatory Activation of Ileal CD8+ Tissue-Resident T Cells Is Dependent on Mucosal LocationSummary

Autor: Lisanne Lutter, Britt Roosenboom, Eelco C. Brand, José J. ter Linde, Bas Oldenburg, Ellen G. van Lochem, Carmen S. Horjus Talabur Horje, Femke van Wijk

Publikováno v: Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 5, Pp 1567-1581 (2021)

Background & Aims: Tissue-resident memory T (Trm) cells, both of the CD4 and CD8 lineage, have been implicated in disease flares in inflammatory bowel disease. However, data are conflicting regarding the profile of human CD8+ Trm cells, with studies

Externí odkaz: https://doaj.org/article/a4509fd606384f5597875baba536cee4

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands

Autor: Bas Oldenburg, Menno R Vriens, Fiona D M van Schaik, Ellen de Bock, Mando D Filipe, Vincent Meij, Okan W Bastian, Herma F Fidder, Milan C Richir

Publikováno v: BMJ Open Gastroenterology, Vol 8, Iss 1 (2021)

Objective COVID-19 has put a strain on regular healthcare worldwide. For inflammatory bowel disease (IBD), gastrointestinal surgeries were postponed and changes in treatment and diagnostic procedures were made. As abrupt changes in treatment regimens

Externí odkaz: https://doaj.org/article/69384c9a8ce441128d1da9a1ba0d8a3d

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

Autor: Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. van der Meulen‐de Jong, Marjolijn Duijvestein

Publikováno v: Alimentary Pharmacology & Therapeutics, 57, 1, pp. 117-126
Alimentary Pharmacology & Therapeutics, 57, 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell
Straatmijer, T, van Schaik, F D M, Bodelier, A G L, Visschedijk, M, de Vries, A C, Ponsioen, C Y, Pierik, M, van Bodegraven, A A, West, R L, de Boer, N K H, Srivastava, N, Romkens, T E H, Hoekstra, J, Oldenburg, B, Dijkstra, G, van der Woude, J C, Löwenberg, M, Mujagic, Z, Biemans, V B C, van der Meulen-de Jong, A E & Duijvestein, M 2023, ' Effectiveness and safety of tofacitinib for ulcerative colitis : two-year results of the ICC Registry ', Alimentary Pharmacology and Therapeutics, vol. 57, no. 1, pp. 117-126 . https://doi.org/10.1111/apt.17248
Alimentary Pharmacology & Therapeutics, 57(1), 117-126. Wiley
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. WILEY

Contains fulltext : 290620.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8627fcaccc449fd1031dddee12b17e7
https://doi.org/10.1111/apt.17248